Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 27, 2006

View Archived Issues

ES-936 suppresses growth of pancreatic tumors in mice

Pierre Fabre profiles its novel atypical antipsychotic candidate

Distinct preclinical activity for PPARgamma partial agonist SVT-002149 as compared to rosiglitazone

Biogen Idec and Alnylam collaborate to develop RNAi therapeutics for PML

Protox seeks Canadian clearance for phase I study of PRX-302 for BPH

Topigen selects TPI-1100 as clinical candidate for COPD

Animal studies show PhG-alpha1 effective via intraperitoneal administration

AZ-004 studied in phase IIa trial for treatment of agitation in schizophrenic patients

Enrollment completed in phase II study of AV-608 for social anxiety disorder

Sanofi-aventis and UCB sign U.S. copromotion agreement for Xyzal

Phase I findings for Azixa warrant initiation of phase II

Merck & Co. discontinues development of MK-0354 for atherosclerosis

PharmAthene awarded Department of Defense contract for Protexia development

First clinical study for Sanofi pasteur's cell culture seasonal influenza vaccine

No statistically significant improvement by PRX-00023 on primary GAD endpoint

Recent Pfizer and Solvay patents disclose new agents for schizophrenia and depression

Therapeutic agents for respiratory disorders described in recent patents

Novel LXRbeta modulators prepared and tested at Wyeth

Gabapentin-lactam derivatives show antidepressant-like activity in vivo

NDA submission for orBec in gastrointestinal GVHD

Grazax approved in E.U.

Soliris filed in E.U. for paroxysmal nocturnal hemoglobinuria

Bayer presents further data on its new PDE11 inhibitor BAY-65-6207

Vasopressin 1A receptor antagonists presented by Azevan

Lilly reports on new beta3-adrenergic receptor agonists as potential antiobesity agents

MK-0364: Merck & Co.'s novel CB1 inverse agonist for the treatment of obesity

Midsize drug deals in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...